Inhibikase Therapeutics, Inc.IKTNASDAQ
Loading
Cost of Revenue Over TimeContracting
Percentile Rank22
3Y CAGR+115.3%
5Y CAGR-40.4%
Year-over-Year Change
Direct costs attributable to producing goods sold
3Y CAGR
+115.3%/yr
vs -79.3%/yr prior
5Y CAGR
-40.4%/yr
Recent acceleration
Acceleration
+194.5pp
Accelerating
Percentile
P22
Within normal range
vs 5Y Ago
0.1x
Contraction
Streak
1 yr
Consecutive growthContracting
| Period | Value | YoY Change |
|---|---|---|
| TTM | $67066.00 | +155.3% |
| 2024 | $26272.00 | -99.8% |
| 2023 | $13.62M | +202463.6% |
| 2022 | $6723.00 | -99.9% |
| 2021 | $11.36M | +1170.9% |
| 2020 | $893802.00 | -65.0% |
| 2019 | $2.55M | -30.0% |
| 2018 | $3.65M | +107.7% |
| 2017 | $1.76M | +107.4% |
| 2016 | $846386.00 | - |